title: Can BuCyE conditioning regimen be an alternative treatment to BEAM at autologous transplantation in malignant lymphoma patients?: a single center experience.
abstract: High-dose chemotherapy (HDC) applied together with autologous stem cell transplantation (ASCT) is a commonly used treatment modality in patients with malignant lymphoma. At present, there is a limited number of studies which compare toxicity and efficacy of various high-dose regimens applied in the treatment of malignant lymphoma. For this reason, the aim of this study was to investigate the efficacy and toxicity of BuCyE (busulfan, cyclophosphamide and etoposide) and BEAM (carmustine, etoposide, cytarabine and melphalan) preparative regimens in the patients with malignant lymphoma scheduled for autologous stem cell transplantation. Between November, 2010 and April, 2015, 42 patients with relapsed or refractory malignant lymphoma who underwent autologous stem cell transplantation following BEAM (n=11) and BuCyE (n=31) preparative regimens were analyzed at Bone Marrow Transplantation Unit of TurgutOzal Medicine Center in Turkey. The groups were compared in terms of patient characteristics, hematopoietic engraftment time, toxicity profiles and survival. No significant differences were detected between the groups with regard to age, gender distribution, international prognostic index, ASCT indications, disease status at the time of ASCT and type of lymphoma (P>0.05). Median number of infused CD34+ cells/kg, neutrophil and platelet engraftment statuses of BuCyE and BEAM groups were found to be similar (P>0.05). More patients in BuCyE group developed mucositis and nausea, but this difference was not statistically significant (P>0.05). A similar statistically insignificant difference was seen in that infectious complications occurred more commonly in BEAM group (P>0.05). Overall survival and event-free survival rates were not significantly different between the groups (P>0.05). BuCyE is a conditioning regimen which can be effectively used as an alternative to BEAM in the patients with malignant lymphoma undergoing ASCT. Moreover, toxicity rates of both regimens are similar. In order to comprehend the effect of each HDC regimen, further evidence-based data obtained from the studies involving larger sample sizes are required.
authors.affiliation: Department of Hematology, Inonu University, Faculty of Medicine Malatya, Turkey.
authors.forename: Ilhami
authors.initials: I
authors.lastname: Berber
authors.affiliation: Department of Hematology, Inonu University, Faculty of Medicine Malatya, Turkey.
authors.forename: Mehmet Ali
authors.initials: MA
authors.lastname: Erkurt
authors.affiliation: Department of Hematology, Inonu University, Faculty of Medicine Malatya, Turkey.
authors.forename: Ilknur
authors.initials: I
authors.lastname: Nizam
authors.affiliation: Department of Hematology, Inonu University, Faculty of Medicine Malatya, Turkey.
authors.forename: Mustafa
authors.initials: M
authors.lastname: Koroglu
authors.affiliation: Department of Hematology, Inonu University, Faculty of Medicine Malatya, Turkey.
authors.forename: Emin
authors.initials: E
authors.lastname: Kaya
authors.affiliation: Department of Hematology, Inonu University, Faculty of Medicine Malatya, Turkey.
authors.forename: Irfan
authors.initials: I
authors.lastname: Kuku
authors.affiliation: Department of Biostatistics and Medical Informatics, Inonu University School of Medicine Malatya, Turkey.
authors.forename: Harika Gozukara
authors.initials: HG
authors.lastname: Bag
keywords: BEAM; BuCyE; autologous transplantation; lymphoma